COL9A1
EmergingCOL9A1 mutations cause multiple epiphyseal dysplasia, a skeletal cartilage growth disorder, diagnosed via genetic testing.
This gene makes part of the collagen that gives cartilage its structure. Mutations cause a skeletal growth disorder affecting the joints, and variations in this gene are also being studied for a possible role in back disc problems, more as a research topic than a treatment-guiding blood test.
COL9A1 encodes a component of type IX collagen, an important structural protein in cartilage that helps organize the cartilage extracellular matrix.
Mutations in COL9A1 cause multiple epiphyseal dysplasia, a skeletal growth disorder affecting joint cartilage development, and variants have also been studied in relation to intervertebral disc degeneration susceptibility.
Diagnosed via genetic testing (COL9A1 sequencing) in patients with characteristic joint pain, early-onset osteoarthritis, and skeletal imaging findings suggestive of epiphyseal dysplasia; disc degeneration association studies remain primarily in the research domain.
No COL9A1-specific therapy exists; management of multiple epiphyseal dysplasia is supportive (pain management, orthopedic monitoring, and joint replacement in severe adult cases), with genetic counseling for affected families.
More of a genetic/research marker than a routine clinical blood test; disc degeneration link remains investigational.
- General genetics/orthopedics reference literature on COL9A1 mutations in multiple epiphyseal dysplasia.